DOI: http://dx.doi.org/10.18203/issn.2455-4510.IntJResOrthop20194832

Bilateral sequential atypical femur fractures in a patient on zoledronic acid therapy: a case report and review of literature

Radhakrishna Kantanavar, Mohan Madhav Desai, Kunal Ajitkumar Shah, Swapneel Sunil Shah

Abstract


Bisphosphonates are mainstay of anti-resorptive therapies for osteoporosis. They prevent osteoporotic fractures by 40 to 70 % in women and men with osteoporosis. Use of these medications is not free from complications. A case of 62 year old female who presented with left thigh pain after trivial fall at home. X-ray diagnosed as atypical femur fracture of left femur which was fixed internally with interlock nailing. On 1st postoperative day, she complained of pain in right thigh. X-ray revealed an atypical femur fracture of left femur shaft which was also fixed internally with nailing. Biochemical investigations were suggestive of effectiveness of zoledronic therapy. We report this first case of bilateral sequential atypical femur fractures that was treated with zoledronate for 2 years. To our knowledge there are reports of oral alendronate therapy with atypical femoral fractures but none on zoledronic acid.

 


Keywords


Atypical femur fractures, Zoledronic acid, Bisphosphonates

Full Text:

PDF

References


Khosla S, Bilezikian JP, Dempster DW, Lewiecki EM, Miller PD, Neer RM, et al. Benefits and risks of bisphosphonate therapy for osteoporosis. J Clin Endocrinol Metab. 2012;97:22720-82.

Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CYC. Severely suppressed bone turnover: A potential complication of alendronate therapy. J Clin Endocrinol Metab. 2005;90:1294-301.

Frost HM. Perspectives: a proposed general model of the “Mechanostat” (Suggestions from a new skeletal-biologic paradigm). Anat Rec. 1996;244:139-47.

Li J, Mashiba T, Burr DB. Bisphosphonate treatment suppresses not only stochastic remodeling but also the targeted repair of microdamage. Calcif Tissue Int. 2001;69:281-6.

Ettinger B, Burr DB, Ritchie RO. Proposed pathogenesis for atypical femoral fractures: lessons from materials research. Bone. 2013;55:495-500.

Kang JS, Won YY, Kim JO, Min BW, Lee KH, Park KK, et al. Atypical femoral fractures after anti-osteoporotic medication: A Korean multicenter study. Int Orthop. 2014;38:1247-53.

Yoon RS, Beebe KS, Benevenia J. Prophylactic bilateral intramedullary femoral nails for bisphosphonate-associated signs of impending subtrochanteric hip fracture. Orthopedics. 2010;33(4).

Weil YA, Rivkin G, Safran O, Liebergall M, Foldes AJ. The outcome of surgically treated femur fractures associated with long-term bisphosphonate use. J Trauma Inj Infect Crit Care. 2011;71:186-90.

Teo BJX, Koh JSB, Goh SK, Png MA, Chua DTC, Howe TS. Post-operative outcomes of atypical femoral subtrochanteric fracture in patients on bisphosphonate therapy. Bone Jt J. 2014;96:658-64.

Cho JW, Oh CW, Leung F, Park KC, Wong MK, Kwek E, et al. Healing of atypical subtrochanteric femur fractures after cephalomedullary nailing: which factors predict union?. J Orthop Trauma. 2017;31:138-45.